FDA Clears Larger Vial Size of Nelarabine Injection in T-ALL and T-LBL

• The FDA approved a larger nelarabine vial size to improve dosing precision and reduce waste in T-ALL and T-LBL treatment.
• Nelarabine is indicated for patients with relapsed or refractory T-ALL and T-LBL after at least two chemotherapy regimens.

Read full article on Targeted Oncology